Research programme: anti-infectives - Essential Therapeutics/Lexicon

Drug Profile

Research programme: anti-infectives - Essential Therapeutics/Lexicon

Alternative Names: Anti-infectives research programme - Essential Therapeutics/Lexicon

Latest Information Update: 24 May 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Essential Therapeutics [CEASED]; Lexicon Genetics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Mycoses; Viral infections

Most Recent Events

  • 24 Oct 2001 Microcide Pharmaceuticals has merged with Althexis to form Essential Therapeutics
  • 26 Jul 2001 Coelacanth Corporation has been acquired by Lexicon Genetics
  • 13 Jun 2000 Preclinical development for Bacterial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top